|
Sep 3
|
Muscle Disease Drug Developer Dyne Therapeutics Stock Plunges After Updated Data From Duchenne Muscular Dystrophy
|
|
Sep 3
|
Dyne Therapeutics Announces Key Leadership Appointments
|
|
Sep 3
|
Dyne Therapeutics Announces New Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented Dystrophin Expression and Functional Improvement in Multiple Cohorts
|
|
Aug 12
|
Dyne Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
|
|
Jul 29
|
Recent Price Trend in Dyne Therapeutics (DYN) is Your Friend, Here's Why
|
|
Jun 24
|
Dyne Therapeutics Presents New Preclinical Data Demonstrating the Potential of the FORCE™ Platform to Deliver Enzyme Replacement Therapy to Muscle and CNS in Pompe Disease
|
|
May 19
|
Dyne Therapeutics to Host Virtual Investor Event to Review New Clinical Data from the ACHIEVE and DELIVER Trials Tomorrow, May 20 at 8:00 a.m. ET
|
|
May 4
|
We're Hopeful That Dyne Therapeutics (NASDAQ:DYN) Will Use Its Cash Wisely
|
|
May 4
|
Dyne Therapeutics Inc (DYN) Q1 2024 Earnings: Aligns with Analyst Projections
|
|
May 2
|
Dyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
|
|
Mar 27
|
Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer
|
|
Mar 27
|
Dyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium
|
|
Mar 25
|
Dyne Therapeutics Announces CEO Transition
|
|
Mar 13
|
Dyne Therapeutics to Present at Stifel 2024 Virtual CNS Days
|
|
Mar 7
|
Dyne Therapeutics Inc (DYN) Reports Encouraging Clinical Data and Financial Growth for Q4 and ...
|
|
Mar 5
|
Dyne Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
|
|
Feb 14
|
Dyne Therapeutics Announces Upcoming Presentations on Initial Clinical Data From its ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients at the 2024 Muscular Dystrophy Association Clinical & Scientific Conference
|
|
Jan 14
|
Institutional owners may ignore Dyne Therapeutics, Inc.'s (NASDAQ:DYN) recent US$56m market cap decline as longer-term profits stay in the green
|
|
Jan 11
|
Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
|
|
Jan 3
|
Dyne Therapeutics Announces Positive Initial Clinical Data from ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients Demonstrating Promise of the FORCE™ Platform in Developing Therapeutics for Rare Muscle Diseases
|